Principia Biopharma Inc. Common Stock
PRNB
PRNB was delisted on the 25th of September, 2020.
115 hedge funds and large institutions have $1.6B invested in Principia Biopharma Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 48 increasing their positions, 11 reducing their positions, and 16 closing their positions.
336% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 11
213% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 16
181% more capital invested
Capital invested by funds: $569M → $1.6B (+$1.03B)
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
42% more funds holding
Funds holding: 81 → 115 (+34)
18% less call options, than puts
Call options by funds: $248K | Put options by funds: $301K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$72.2M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$64.1M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$62.8M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$49.4M |
| 5 |
BlackRock
New York
|
+$28.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$45.3M |
| 2 |
NLVP
New Leaf Venture Partners
New York
|
-$40.4M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$15.8M |
| 4 |
RI
RTW Investments
New York
|
-$7.65M |
| 5 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$2.86M |
PRNB Hedge Fund Activity: Q4 2019 in Review
115 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Principia Biopharma Inc. Common Stock (PRNB) for Q4 2019, worth a combined $1.6B — up 181% from $569M a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new PRNB positions and 16 closed out — a net gain of 34 holders — while 48 added to existing stakes and 11 trimmed.
The largest buyer was Redmile Group, adding an estimated $72.2M. The largest seller was OrbiMed, exiting entirely with an estimated $45.3M sold.
- 115 institutional investors held Principia Biopharma Inc. Common Stock (PRNB) as of Q4 2019, up from 81 in Q3 2019.
- Funds reported $1.6B of Principia Biopharma Inc. Common Stock stock for Q4 2019, up 181% quarter-over-quarter.
- 50 funds opened new Principia Biopharma Inc. Common Stock positions in Q4 2019 and 16 closed out, a net change of +34 holders.
- The largest Principia Biopharma Inc. Common Stock buyer in Q4 2019 was Redmile Group, an estimated $72.2M added.
- The largest Principia Biopharma Inc. Common Stock seller in Q4 2019 was OrbiMed, an estimated $45.3M sold.
Based on aggregated 13F filings for Q4 2019.